1. Ledford H (2015) Cancer-fighting viruses win approval. Nature 526:622–623
2. European Medicines Agency. The Committee for Medicinal Products for Human Use (CHMP) assessment report for Imlygic. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002771/WC500201082.pdf . Accessed 1 March 2016
3. European Medicines Agency. The Committee for Medicinal Products for Human Use (CHMP) summary of product charactersitics for Imlygic. 2015. http://www.medicines.org.uk/emc/medicine/31351 . Accessed 18 April 2016
4. Therapeutic Goods Administration. Australian Public Assessment Report for Talimogene Laherparepvec. 2016. https://www.tga.gov.au/auspar/auspar-talimogene-laherparepvec . Accessed 14 Nov 2016
5. Shen Y, Nemunaitis J (2006) Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 13:975–992